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Impact of nicotine replacement 
therapy as an adjunct to anti-
tuberculosis treatment and 
behaviour change counselling 
in newly diagnosed pulmonary 
tuberculosis patients: an open-
label, randomised controlled trial
Surendra Kumar Sharma1,2,8, Alladi Mohan3, Achintya Dinesh Singh2, Hridesh Mishra2,  
Sonali Jhanjee4, Ravindra Mohan Pandey5, Binit Kumar Singh2, Rohini Sharma2,  
Prakash Babu Pallipamu3, Madhukar Pai6 & Keertan Dheda7
We evaluated the impact of intensive smoking cessation activities as an adjunct to anti-tuberculosis 
treatment on patient-related treatment outcomes. In this open-label, randomised controlled trial, self-
reporting smokers with pulmonary tuberculosis who initiated standard anti-tuberculosis treatment 
were randomised to either nicotine replacement therapy and behaviour change counselling (n = 400) 
or counselling alone (n = 400) provided at baseline and two follow-up visits. The primary outcomes 
were change in TBscore at 24-weeks and culture conversion at 8-weeks. Biochemical smoking quit rates 
defined as serum cotinine levels <10 ng/mL and/or exhaled carbon monoxide levels <6 ppm (47·8% 
vs 32·4%, p-value =< 0·001) and self-reported quit rates (69.3% vs 38·7%, p-value =< 0·001) were 
significantly higher in the intervention arm at 24-weeks. Though the TBscores at 24 weeks (95% CI) were 
lower in the intervention arm [2·07 (1·98, 2·17) versus 2.12 (2·02, 2·21)], the difference was not clinically 
meaningful. Patients in the control arm required treatment extension more often than intervention 
arm (6·4% vs 2·6%, p-value = 0·02). Combining nicotine replacement therapy with behaviour change 
counselling resulted in significantly higher quit rates and lower cotinine levels, however, impact on 
patient-related (TBscore) or microbiological outcomes (culture conversion) were not seen.
Tuberculosis (TB) is a major cause of global morbidity and mortality with an estimated 1.3 million TB deaths 
among human immunodeficiency virus (HIV) negative people and 10·4 million incident cases in 20161. Among 
22 high TB burden countries, India contributes to over one-quarter of the global TB burden1. Tobacco smoking 
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the second largest contributor to global disability-adjusted life years after systolic hypertension2, is highly prev-
alent in the middle and low-income countries, and about 12·4% of adult population (21·9% in adult males and 
2·3% in adult females) in India are estimated to be smokers3 with prevalence as high as 70% in some states4.
Smoking is strongly associated with TB disease and has a substantial population-attributable risk for TB infec-
tion, active TB disease, and mortality. Adult smokers and individuals exposed to second-hand smoke have a 
higher risk of acquiring pulmonary tuberculosis (PTB) than non-smokers, and the odds are even greater in heavy 
smokers5,6. Also smokers have delayed sputum culture conversion, frequently require treatment extensions, have 
higher treatment failure and relapse rates and greater absolute mortality as compared to non-smokers7–9.
Intuitively, integrating smoking cessation strategies with anti-tuberculosis treatment (ATT) should have a 
beneficial impact on TB treatment-related outcomes. Intensive smoking cessation methods like nicotine replace-
ment therapy (NRT) by increasing smoking abstinence during ATT, should yield better treatment outcomes. 
A recent Cochrane systematic review has expressed concern over the lack of high quality evidence to endorse 
integration of smoking cessation activities along with ATT10. This is a critical unmet need because investment 
of substantial resources into smoking cessation interventions can only be justified and implemented if there are 
proven benefits to patient important outcomes.
To address this knowledge gap, the present study was carried out with the objective of studying the impact 
of NRT along with behaviour change counselling for smoking cessation on TB treatment-related outcomes in a 
controlled, clinical trial. The control arm received only behaviour change counselling along with anti-TB therapy.
Results
Study subjects. The trial was conducted from 13 November 2010 to 03 September 2016. Of the 800 patients 
enrolled, one patient in the intervention arm and three patients in the control arm was later diagnosed as multid-
rug-resistant TB and one enrolled patient (intervention arm) died in a road traffic accident, 37 patients were lost 
to follow-up (Fig. 1).
Baseline Characteristics.  Table 1 details baseline characteristics of the participants. All characteristics were 
comparable at baseline. Majority of the patients were male. Four patients (two in each arm) were sputum smear 
positive but culture negative at baseline. These patients were not excluded from the study as their culture reports 
only became available after four weeks of enrolment.
Endpoint and follow-up. Primary outcome. Modified intention to treat (mITT) analysis showed signifi-
cant decline in TBscore from baseline to eighth week in both the arms. The decline in the intervention arm was 
significantly higher (difference in decline = 0·29, 95%CI = 0·007, 0·59; p value = 0·04). The direction of change and 
magnitude of difference were similar in per protocol analysis (0·32 95%CI = 0·058, 0·59; p value = 0·016). However, 
the minimal clinically important difference (MCID) was not achieved. The TBscore at 24-week was similar in 
both the arms (intervention arm = 2.38 ± 1·6, control arm = 2.37 ± 1·5, difference = 0·006, 95% CI = −0·22, 0·21; 
p value = 0·95). Sputum culture conversion was achieved in all the patients in both the arms at 8 weeks (Table 2). 
There was no statistical difference in sputum culture conversion rates (Fig. 2) in both the arms (Hazard ratio: 0·97, 
95%C.I = 0·84, 1·12; p value = 0.709). Details of weekly sputum culture conversion: Supplement Table s3.
Figure 1. Trial profile. ATT = anti-tuberculosis treatment; HIV = human immunodeficiency virus; MDR-TB = 
multidrug-resistant tuberculosis.
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Secondary outcomes. All patients in both the groups achieved negative sputum smear results by the end of 
8 weeks. On weekly follow-up, 237 patients (61.7%) in the intervention arm were sputum smear negative and 
51(13.2%) patients were not producing sputum at fourth week, while 206(53·7%) patients were sputum smear 
negative and 35(9·1%) were not producing sputum in the control arm, (p value = 0·001). In the fifth-week signif-
icantly higher proportion of patients in the intervention arm had negative sputum smear or were not producing 
sputum than control arm (p value = 0.01). All patients were sputum smear negative at the end of seventh week. 
Time to sputum smear conversion was early in the intervention arm (hazard ratio = 1·13, 95%C.I = 1·03, 1·37; 
p value = 0·015 Fig. 3). As per the decision of the treating medical officers, 10 patients (2·6%) in the interven-
tion arm required treatment extension at the end of six months for three more months compared to 24 patients 
(6·4%) in the control arm (p value = 0·02). Eleven patients (2·9%) in the intervention arm and 12 patients (3·2%) 
in the control arm had relapse and were started Category II ATT as per Revised National Tuberculosis Control 
Programme (RNTCP) guidelines. Median time to relapse was 3 years (IQR = 2–3) in the intervention arm and 
1·5 years in control arm (IQR = 0·8–2) (0·95, 95% CI = 0·24, 1·74; p value = 0·011).
The self-reported quit rates (69·3% vs 38·7%, p value < 0·001) as well as biochemical quitting (47.8% vs 32.4%, 
p value < 0.001) at the end of 24-week (Table 2) were higher in intervention arm than control arm. The mean 
reduction in serum cotinine levels, BAT results and FTND scores were also significantly greater in the inter-
vention arm (Table 3). Increase in body weight across both the arms at the end of 24-week was similar (−0·88, 
C.I = −1·8, 0·07, p value = 0·76) and subsequent to treatment completion most patients in both arms reported 
re-initiation of tobacco smoking (80·6% vs 79·7%).
Characteristics
NRT + counselling
(n = 400)
Counselling alone
(n = 400)
Age (years) 34·9 ± 11·9 34·23 ± 11·9
Gender
 Male 398 400
 Female 02 00
Smoking pack-years 5·13 ± 7·1 4·89 ± 6·9
Breath analysis test(ppm) 17·79 ± 6·6 17·48 ± 7·1
FTND score 6·85 ± 1·1 6·73 ± 1·1
Serum cotinine level (ng/mL) 97·22 ± 5·3 97·55 ± 5·6
Alcohol intake
 Non-alcoholic 281(70·2%) 285(71·2%)
 Alcoholic 119(29·8%) 115(28·8%)
Body mass index (kg/m2) 18·72 ± 2·6 18·39 ± 2·6
Radiological findings
 Normal 151(37·8%) 137(34·3%)
 Unilateral 244(61·0%) 256(64·0%)
 Bilateral 5(1·2%) 7(1·8%)
Radiological severity
 Minimal lesion 15(3·7%) 24(6·0%)
 Moderately-advanced 264(66·0%) 257(64·2%)
 Far-advanced 121(30·2%) 119(29·7%)
Cavitary lesion
 Cavitary 8(2·0%) 9(2·2%)
 Non-cavitary 392(98·0%) 391(97·7%)
Baseline
 Negative 00 00
 Scanty 163(40·7%) 162(40·5%)
 1+ 130(32·5%) 148(37·0)
 2+ 92(23·0%) 71(17·7%)
 3+ 15(3·7%) 19(4·7%)
TBscore at baseline 7·87 ± 1·2 7·84 ± 1·3
Table 1. Comparison of baseline characteristics between the two arms. Values are presented as mean ± SD, 
categorical variables are presented in frequencies (percentage)· Abbreviations: NRT = nicotine replacement 
therapy, BMI = Body mass index, FTND = Fagerstrom test for nicotine dependence, Definition: Bidi = Hand 
rolled cigarettes containing tobacco wrapped in a tendu or temburni leaf, Smoking pack year = (Number 
of bidi/cigarette smoked per day × Number of years smoked)/20 (1 pack has 20 cigarettes/bidis) TBscore = 
validated, composite marker of tuberculosis related clinical outcome· Difference in various parameters between 
the two arms were not statistically significant.
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Discussion
This is the first randomised trial to holistically assess the impact of combined NRT with behaviour change coun-
selling on smoking cessation and its role in improving TB treatment outcomes. The key finding of this study is 
that although intervention of NRT combined with counselling achieved higher smoking cessation and quit rates 
and a greater reduction in TB score was seen in intervention arm, the difference was below the MCID, and both 
the arms had similar sputum culture conversion rates. However, the intervention arm had earlier sputum smear 
conversion beginning from the third week up to the fifth week. Also, treatment extension rates were higher in the 
control arm compared to the intervention arm.
TBscore, the primary outcome, did not meaningfully change at 8 and 24 weeks. NRT was provided only for the 
initial six weeks after which both the arms received the same counselling. The reduction in smoking seen across 
both the arms may have contributed to the similar decline of TB score. The mean scores at the end of 8-weeks 
in our study (intervention arm = 3·1 ± 1.9, control arm = 3·3 ± 1.9) are similar to the original study on TBscore 
by Wejse et al. (3·0 ± 2.3) providing credibility to our results11. Although we could not show impact using proxy 
measures (TBscore) we wondered if a larger study could have shown an impact on outcomes such as treatment 
failure, cure rates, and relapse? This seems less likely as our statistical calculations were robust and conservative 
(powered to detect a 0·5 point difference in the TBscore) and we were able to show significant improvement in 
quit rates between the arms.
Outcomes Counselling+ NRT Counselling alone Difference (95% C.I.) p value
mITT analysis
Primary outcome:
TB score
n
Baseline
Eight week
Change
24 weeks
Change
398
7·87 ± 1·2
3·10 ± 1·9
4·76 ± 2·05
2·38 ± 1·6
5·48 ± 1·8
397
7·82 ± 1·3
3·36 ± 1·9
4·46 ± 2·12
2·37 ± 1·5
5·45 ± 1·8
−0·04 (−0·22, 0·13)
0·25 (−0·02, 0·52)
0·29 (0·007, 0·59)
0·006 (0·22, −0·21)
0·039 (0·29, −0·21)
0·61
0·07
0·045
0·95
0.72
Sputum culture conversion
n
Baseline
8-weeks
398
02(0·5%)
379(95·2%)
397
02(0·5%)
379(95·5%)
—
—
1·00
1·00
Per Protocol analysis
TBscore
n
Baseline
8-weeks
Change
24-weeks
Change
379
7·84 ± 1·19
2·84 ± 1·60
5·00 ± 1·79
2·07 ± 0·94
5·76 ± 1·34
379
7·83 ± 1·32
3·15 ± 1·72
4·67 ± 1·92
2·12 ± 0·96
5·70 ± 1·43
0·01(0·16, −0·19)
0·31(0·07, 0·54)
0·32(0·058, 0·59)
0·04(−0·09, 0·17)
0·05(−0·14, 0·25)
0·88
0·010
0·016
0·54
0·58
Sputum culture conversion
n
Baseline
8-weeks
379
02
379 (100%)
379
02
379(100%)
—
—
1·000
1·000
Secondary Outcome
Sputum smear Conversion
n
Baseline
8-weeks
378
00
378
378
00
379
—
— 1·000
Weight (kg)(Mean ± SD)
Baseline
24-weeks 
Change
49·45 ± 6·9
53·47 ± 6·9
3·1 ± 2·3
50·22 ± 7·3
52·58 ± 6·5
3·1 ± 1·9
−0·78(−1·8, 0·2)
0·04(−0·2, 0·3)
−0·88(−1·8,0·07)
0·120
0·070
0·760
Self-reported quit rate*
n
Eight week
24-weeks
379
222(58·5%)
263(69·3%)
379
91(24·01%)
147(38·7%)
0·4(0·29, 0·42)
0·3(0·23, 0·36)
<0·001
<0·001
Biochemical quit rate
Eight week
24-weeks
73(19·3%)
180(47·8%)
47(12·5%)
121(32·4%)
0·07(0·02, 0·12)
0·15(0·08, 0·21)
<0·001
<0·001
Table 2. Comparison of various outcomes between the two arms. One patient from the counselling + NRT arm 
and three from the counselling arm were excluded from the analysis as they were diagnosed with multidrug-
resistant tuberculosis infection, one patient in the counselling + NRT arm died in a road traffic accident before 
the first follow-up and was excluded from the analysis. Abbreviations: mITT = modified intention to treat, 
ATT = Anti-tuberculosis therapy NRT = nicotine replacement therapy, C.I. = confidencce interval. Data are 
presented as mean ± SD· Values of significance assessed using Student’s t-test, TBscore = validated, composite 
marker of tuberculosis related clinical outcome, *Self reported, Biochemical quit rates = patients with serum 
cotinine <10 ng/mL and/or Breath analysis test <6 parts per million.
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Though various studies have shown an association between smoking and delayed culture conversion7,8, the 
impact of smoking cessation on TB treatment outcomes has never been conclusively demonstrated. Shaler et al. 
found continuous and not discontinuous exposure to cigarette smoke the major cause of impediment of immune 
function12. The mean decline of smoking across both the arms may have had led to immune recovery in both the 
arms. It is possible that we could have observed a significant difference in the TBscore and sputum culture conver-
sion during the intensive phase of treatment if, one of the arms had ‘usual standard of care’ which is what occurs 
in routine clinical practice where no counselling is provided. However, having such an arm was deemed unethical 
by our research committees. We therefore propose that behaviour change counselling should be an integral part of 
the National Tuberculosis Program similar to pre-test and post-test counselling done in HIV/ AIDS. Healthcare 
providers should be adequately trained to acquire counselling skills.
A recent study by Awaisu et al. found a trend towards earlier sputum smear conversions at 8-weeks with 
higher sputum smear negativity at 24 weeks in the intervention group receiving counselling and NRT (100% vs 
93·9%)13. However, this study13 had several limitations including a non-randomised study design resulting in 
selection bias, high drop-out rates during the course of the study, non-uniformity of the baseline characteristics 
between the groups, and Hawthorne effect in the intervention arm. Also, only smokers who were motivated to 
quit smoking were enrolled in the intervention group and drug therapy was modified as per individual patient’s 
adherence to smoking cessation. Due to these drawbacks, findings of that study cannot be generalized to smokers. 
Nonetheless, the trend of early sputum smear conversion shown in that study provides corroborative evidence to 
the impact of interventions on sputum smear results observed in our study.
In the present trial, delayed radiological improvement and treatment extensions were more frequent in control 
arm than intervention arm (6·4% vs 2·6%, p value = 0·02). The median time to relapse in the intervention arm 
Figure 2. Kaplan-Meier curve showing sputum culture conversion Footnotes: HR- Hazard ratio, 
C·I = confidence interval, NRT = nicotine replacement therapy.
Figure 3. Kaplan-Meier curve showing sputum smear conversion Footnotes: HR = Hazard ratio, C·I = confidence 
interval, NRT = nicotine replacement therapy.
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was 3 years as compared to 1·5 years in control arm. These results are congruent with previously reported studies 
implicating the role of continued smoking in delayed improvement, treatment extension and relapse7,8,13,14.
The biochemical quit rates found in our study at six months were 47.8% and 32·4% in the intervention and 
control arms, respectively. Both, serum cotinine and exhaled breath carbon monoxide levels were measured to 
avoid false negative results due to omissions and negative self-reporting15. Assessment of BAT levels accounted for 
any false elevation in serum cotinine levels due to smokeless tobacco use or nicotine replacement therapy16. These 
results are similar to a recent study17 in smokers with TB which found abstinence rates of 71·7% in the group 
receiving counselling along with slow-release bupropion as compared to counselling alone (33·9%), and a no 
counselling group (9·8%).The authors did not report the impact on treatment-related outcomes. Our findings also 
receive credence from a recent Cochrane systematic review, which concluded that combined nicotine replace-
ment and counselling methods are better for smoking cessation than a casual or brief advice or no intervention18. 
Patients concerns about their illness and desire to achieve faster recovery can itself motivate them to quit smok-
ing19. This, along with focused counselling led to reduction in all smoking-related parameters across both the 
arms. However, a greater reduction in the intervention arm may be attributed to the role of NRT administration 
in further boosting their motivation levels by ameliorating the cravings associated with nicotine addiction20. 
On telephonic enquiry, high rate of re-initiation of tobacco smoking in both arms after completion of therapy, 
emphasises the need for continuous reinforcement of counselling in the highly smoking dependent group. This 
was not the objective of the study as our smoking cessation interventions were provided only up to six weeks.
The trial has many strengths. Adherence to the smoking cessation strategies was monitored by subjective as 
well as objective assessments. Outcomes were assessed using clinical parameters as well as culture and sputum 
smear techniques. TBscore was found to be an effective tool for clinical assessment and can be incorporated for 
monitoring of patients on anti-TB therapy. The trial was conducted in several DOT centres of two trial sites under 
RNTCP and demonstrates the feasibility of integrating smoking cessation strategy into the national TB control 
programmes. The study has wide applicability globally to combat ongoing and colliding epidemics of tobacco 
smoking and TB. However, a number of limitations should be noted. The trial did not have a “drug treatment 
only” arm without counselling. Also, the results of the study are ascribable to predominantly a single centre. 
The absent sputum production in a significant proportion of patients led to high loss to follow-up of the culture 
reports. Socio-economic factors like literacy, monthly income which can confound the effects of smoking cessa-
tion methods on quitting were not noted during the study.
Overall our findings suggest that counselling alone was also found to be feasible and effective method for 
smoking cessation, however combination therapy had higher compliance. Though the clinical improvement seen 
in the study was not meaningful, the greater reductions seen in the NRT with counselling arm could have been 
significant if compared against a control arm likely to be seen in routine clinical practice. Larger pragmatic studies 
are now required to determine if smoking cessation interventions can impact important clinical outcomes such as 
treatment failure, cure, relapse and mortality.
Test
Counselling+ NRT Counselling alone
Difference (95% C·I.) p valuen Mean ± SD N Mean ± SD
Serum cotinine levels (ng/mL)
Baseline 328 97·24 ± 5·3 320 97·52 ± 5·59 0·27 (−0·56, 1·12) 0·510
2nd week 317 86·06 ± 15·5 311 90·60 ± 13·87 4·53 (2·23, 6·84) 0·001
4th week 314 71·87 ± 22·7 305 78·38 ± 18·01 6·54 (3·26, 9·74) 0·001
2nd month 309 57·86 ± 28·1 300 66·63 ± 21·9 8·77 (4·75, 12·79) 0·001
6th month 307 45·87 ± 32·7 297 55·12 ± 27·31 9·25 (4·42, 14·07) 0·002
Total change 51·48 ± 33·5 43·36 ± 27·09 9·11 (4·23, 13·99) 0·0003
BAT (ppm)
Baseline 387 17·82 ± 6·68 391 17·52 ± 7·13 −0·30 (−1·27, 0·66) 0·540
2nd week 375 14·19 ± 6·12 380 14·24 ± 5·48 0·005 (−0·78, 0·88) 0·900
4th week 371 11·21 ± 4·85 374 11·25 ± 4·37 0·04 (−0·62, 0·71) 0·890
2nd month 368 9·39 ± 3·95 370 10·12 ±  5·62 0·73 (0·029, 1·43) 0·040
6th month 375 7·82 ± 3·29 372 8·51 ± 3·2 0·69 (0·22, 1·15) 0·003
Total change 9·8 ± 6·2 8·8 ± 6·9 0·94 (0·14, 1·90) 0·053
FTND
Baseline 398 6·85 ± 1·06 397 6·73 ± 1·13 −0·11 (0·27, 0·34) 0·120
2nd week 387 4·49 ± 1·39 390 4·93 ± 1·36 0·44 (0·24, 0·63) 0·001
4th week 384 2·84 ± 1·58 384 3·46 ± 1·5 0·62 (0·40, 0·84) 0·001
2nd month 380 1·58 ± 1·4 380 2·54 ± 1·52 0·96 (0·75, 1·16) 0·001
6th month 375 1·38 ± 1·25 375 2·13 ± 1·34 0·75 (0·56,·93) 0·001
Total change 5·45 ± 1·6 4·61 ± 1·8 0·83 (0·59, 1·07) 0·001
Table 3. Comparison of serum cotinine levels, breath analysis test, FTND levels between the two arms. 
mITT = modified intention to treat, ATT = Anti-tuberculosis therapy, NRT = nicotine replacement therapy 
BAT = Breath analysis test, FTND = Fagerstrom Test for Nicotine Dependence, C.I. = confidencce interval.
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Methods
Study design and Participants. We conducted a two-centre open-label, randomised, controlled, clinical 
trial in India. Trial centres were at the All India Institute of Medical Sciences (AIIMS), New Delhi and neighbour-
ing tuberculosis and chest clinics in the National Capital Region of Delhi and the Sri Venkateswara Institute of 
Medical sciences (SVIMS), Tirupati, Andhra Pradesh.
All adult patients (>18years) with newly diagnosed sputum-positive pulmonary tuberculosis with 
self-reported history of current cigarette/rolled tendu or temburni leaf (bidi) smoking (more than 10 per day, 
every day for at least two months), providing written informed consent were recruited by invitation.
Monoresistant TB, multidrug-resistant TB, extensively drug-resistant TB cases21 and patients who had 
received ATT for more than 1-week were excluded from the trial. Patients with known contraindications to 
the use of NRT like myocardial infarction within last six months or history of peripheral vascular disease 
were excluded from the study. Patients with asthma, depression, on immunosuppressive therapy and HIV-TB 
co-infected patients were also excluded from the study. Ethical clearance was obtained from AIIMS, New Delhi 
institutional ethics committee and SVIMS, Tirupati institutional ethics committee. The trial was conducted as 
per Good Clinical Practice guidelines. The trial is registered at ClincalTrials.gov: NCT01517022 on 23/06/2011. 
Protocol available at: https://clinicaltrials.gov/ct2/show/NCT01517022.
Randomisation. Patients were randomised in a 1:1 ratio to the arm receiving behaviour change counselling 
with NRT in the form of nicotine chewing gums (intervention arm) or only behaviour change counselling (con-
trol arm). Randomisation was performed by generation of random numbers through sequentially numbered, 
opaque sealed envelopes using a block randomisation scheme with variable block size.
Procedures. All the patients, irrespective of the allocation, received intermittent, ATT as per the RNTCP 
guidelines which supplies drugs free-of-cost on an alternate-day schedule. During the initial Intensive Phase, iso-
niazid(H), rifampicin(R), ethambutol(E) and pyrazinamide(Z) were provided thrice weekly on every alternate day 
for two months under direct supervision of the healthcare worker for newly diagnosed pulmonary TB patients22. 
It was followed by a Continuation Phase of H and R thrice weekly for the next four months. In this phase, the first 
dose of the week was directly supervised and the remaining two doses were self-administered by patients.
The intervention package for smoking cessation comprised:
Behaviour change counselling. Patients in both arms were provided with individual behavioural counselling 
at baseline (day of enrolment in the study), second and fourth week, each session lasted for around 10 min-
utes. It was designed to enhance awareness about the harmful effects of smoking on health, economy and on 
other family members. They were provided with problem solving/skills training techniques to handle craving, 
withdrawal, and avoid relapse. Information was reinforced by providing pamphlets and educational materials at 
each follow-up visit. The educational materials prepared by The Union, American College of Chest Physicians 
and “Cease smoking today” guidelines were used after translating into local languages (Hindi, Punjabi and 
Telugu)23–25. Counselling was imparted by healthcare workers who were trained by an expert (psychiatrist) in 
smoking cessation over two days. Their efficiency was periodically assessed by the investigators and retraining 
was provided if deemed necessary.
Nicotine replacement therapy (NRT). Patients in the intervention arm were also provided with nicotine chewing 
gums (nicogum) of two mg or four mg for six weeks. Two mg nicogum was administered to patients smoking up 
to 25 bidis/cigarettes/day, whereas four mg nicogum was given to patients smoking more than 25 bidis/cigarettes/
day. They were provided the chewing gums at baseline, the second week visit and the fourth week visit. They were 
advised to chew the gum till they get a flavour, then park it between the cheek and gums, and to restart chewing 
once the taste fades. Patients were instructed to use the gum at fixed intervals throughout the day and if there was 
additional craving; use of more than 24 gums in a day was discouraged26.
Outcome assessment. TBscore was assessed by the medical healthcare workers under the supervision of 
doctors posted in various trial centres on the 8-weeks and 24-weeks follow-up visits (Supplement Table s1). TBscore 
assesses five symptoms namely cough, hemoptysis, dyspnea, chest pain and night sweats. Each of these symptoms 
if present are given one point. Objective assessments include anemic conjunctiva, tachycardia (heart rate more than 
100), any positive findings on lung auscultation, body mass index (BMI) less than 18 kg/m2, axillary temperature 
(more than 38 °C) and mid upper arm circumference (MUAC) less than 220 mm. All of these parameters were pro-
vided one point each. If the BMI was less than 16.5 kg/m2 or the MUAC was less than 200 mm the patients were pro-
vided an additional one point. The TBscore correlates with disease severity and also predicts mortality due to TB11,27.
Sputum smear microscopy for acid-fast bacilli was done at baseline and at each follow-up visit for all patients 
who were producing sputum. Sputum induction techniques were not used. Each slide was made directly from one 
sample; staining, microscopy and bacillary grading were done as per standard RNTCP guidelines28.
Sputum culture using solid and liquid culture media were done at baseline, 8-weeks and 24-weeks. Processed 
samples were inoculated into MGIT-960 non-radiometric automated isolation system. Positive cultures were con-
firmed using immunochromatographic assay kit29. Baseline in-vitro anti-TB drug susceptibility testing (DST) for 
isoniazid H, R, E and S was done for all patients by inoculation on Lowenstein-Jensen media as per the standard 
operating procedure30 or inoculation on BACTEC MGIT-960 system as per the standard operating procedure29. 
Susceptibility testing for Z was not done, as it is technically difficult and the gold standard technique for Z resist-
ance31 was outside the purview of this study. GenoType MTBDRplus line probe assay was also performed as per 
the World Health Organization (WHO) recommendations on all culture positive isolates32.
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Smoking cessation parameters. Smoking cessation was assessed both subjectively and objectively at 
all follow-up visits. Serum cotinine levels were measured using enzyme-linked immunosorbent assay method. 
Breath analysis test (BAT) assessing the exhaled carbon monoxide level was done employing PICO Smoke 
analyser carbon monoxide monitor (Technical details supplement Table: s2). Fagerstrom test for nicotine depend-
ence (FTND)33 assessed subjective dependence on smoking. A chest X-ray was performed at baseline and at 24 
weeks follow-up visit and the pulmonary involvement was classified as described previously34.
Follow-up. Patients were followed-up at 2-weeks, 4-weeks, 8-weeks and 24-weeks at their nearest TB centre/
chest clinic. In case of loss to follow-up, patients were telephonically contacted or the healthcare workers visited 
their homes to persuade them back into the study. After treatment completion, patients were telephonically con-
tacted every 4–6 months about their general health status, smoking habits, etc. Also the patients were advised to 
contact the healthcare workers if they experienced recurrence of symptoms.
Outcome. The primary outcome was a change in the TBscore at 24-weeks and sputum culture conversion 
at eight-week. Secondary outcomes were time to sputum smear conversion, weight gain at 24 weeks, number of 
patients who have quit smoking by 24-week, and mortality by 24-week. WHO guidelines were used for defining 
treatment failure rates, cure rates and default rates21. Quit rates were both self-reported smoking abstinence and 
biochemical quit rates defined as serum cotinine levels less than 10 ng/mL or BAT less than six parts per million.
Patients enrolled in the study after January 2014 at the AIIMS centre were followed-up on a weekly basis till 
the eight-week with sputum culture and smear tests. This ensured detecting early sputum culture and smear con-
versions but did not influence the originally decided outcome in any manner. The original protocol was continued 
at the second centre, SVIMS.
Statistical analysis. The sample size was calculated on the basis of the primary outcome of TBscore11. Wejse 
et al. found that the MCID was just above 1 point (i.e. 1 sign/symptom or a change in BMI/MUAC). Although this 
difference is relevant when comparing overall scores or groups of patients, the authors found that an anchor based 
approach of a 25% change in baseline score was more practical in terms of defining clinical improvement. We 
conservatively assumed that the difference between the arms will be only 0·5 point (approximately 25% reduction 
in the TBscore from baseline to the end of 24 weeks). We also assumed, based on previous studies, that the within 
group standard deviation will be two points in both arms. We needed 335 patients to achieve power of 90% with 
5% two-sided level of significance. Also, to account for the early deaths, loss to follow-up and withdrawals we 
inflated this number by 20% and required 400 patients in each arm.
Statistical analysis was carried out using STATA 12·0 (College Station, Texas, USA). Data were presented as 
number (percentage) or mean ± SD/median (minimum-maximum) as appropriate. Baseline categorical varia-
bles were compared between the groups using Chi-square test/Fischer’s exact test and continuous variables were 
compared using Student’s ‘t’ test/Wilcoxan ranksum test. To analyse the outcomes of the study both mITT and 
perprotocol (pp) were carried out. The TBscore was compared using Student’s ‘t’ test. The sputum culture conver-
sion and smear conversion were compared using z-test. The results were presented as change over time (95% CI). 
Hazard ratios were calculated using Cox regression analysis.
Data availability statement. All data generated or analysed during this study are included in this pub-
lished article (and its Supplementary Information files).
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